

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/856,319		Hidetoshi Uemura	UEMURA 5	6685
1444 7.	7590 11/04/2003		EXAMINER	
BROWDY AND NEIMARK, P.L.L.C.			SULLIVAN, DANIEL M	
624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1636	

DATE MAILED: 11/04/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/856,319	UEMURA ET AL
Advisory Action	Examiner	Art Unit
	Daniel M Sullivan	1636
The MAILING DATE of this communication app	pears on the cover sheet with the	correspondence address
THE REPLY FILED 23 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appel Examination (RCE) in compliance with 37 CFR 1.114.	avoid abandonment of this applic 1) a timely filed amendment whic	ation. A proper reply to a characteristic at the application in
PERIOD FOR R	EPLY [check either a) or b)]	
 a)	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailir	ng date of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date o (2) as set forth in (b) above, if checked. Any reply received by the Off timely filed, may reduce any earned patent term adjustment. See 37	of extension and the corresponding amount of the shortened statutory period for reply fice later than three months after the ma	ount of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant 37 CFR 1.192(a), or any extension thereof (37 CF		
2. \boxtimes The proposed amendment(s) will not be entered by	pecause:	
(a) 🛛 they raise new issues that would require furth	ner consideration and/or search (see NOTE below);
(b) \square they raise the issue of new matter (see Note	below);	
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mate	erially reducing or simplifying the
(d) they present additional claims without cance	ling a corresponding number of f	finally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following rejection	ction(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted in a se	eparate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request fo application in condition for allowance because: Set		idered but does NOT place the
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>20-26,32,33,38,39,42</u> and 43.		
Claim(s) withdrawn from consideration: 11-19,27-	31,35-37,40 and 41.	
8. The proposed drawing correction filed on is		proved by the Examiner.
9. Note the attached Information Disclosure Stateme		
10. Other:	<u> </u>	PRIMARY EXAMINER

Continuation of 2. NOTE: According to the proposed amendment, claims 23 and 32 would be limited to determining the presence or amount of a protein consisting of the amino acid sequence of residues 1-231 of SEQ ID NO: 2 or 4. As even an antibody raised against a protein consisting of residues 1-231 of SEQ ID NO: 2 or 4 would not be able to distinguish proteins consisting of that sequence from proteins comprising that sequence, it is unclear how the method steps set forth would determine the presence or amount of a protein consisting of only residues 1-231 of SEQ ID NO: 2 or 4.

Continuation of 5. does NOT place the application in condition for allowance because: Applicant's arguments are predicated on the amendments to the claims filed therewith. As the amendments have not been entered, the arguments are moot. It is noted, however, that the proposed amendments would not overcome rejection of 20, 21, 23, 24, 25, 26, 33, 38 and 39 under 35 U.S.C. 102(b) as anticipated by Reseland et al. and claim 22 under 35 U.S.C. 103(a) as being unpatentable over Reseland et al. in view of Antibodies. Reseland et al. teaches antibodies raised against peptides that are comprised within residues 1-231 of SEQ ID NO: 2 or 4. Therefore, the antibody or Reseland et al. would react with a protein consisting of residues 1-231 of SEQ ID NO: 2 or 4. Furthermore, the proposed amendment to claim 42 does not fully address the grounds of rejection under 35 U.S.C. 112, first paragraph (enablement)..